BELINDA MILLER: Open Payments
NPI 1295021053 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,014 in 44 payments from 9 companies in 2025. Trend: 2023 $1,117 · 2024 $1,172 · 2025 $1,014
Food & beverage: $1,014
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 14 | $379 |
| Alkermes, Inc. | 9 | $188 |
| Otsuka America Pharmaceutical, Inc. | 8 | $175 |
| Lundbeck LLC | 5 | $98 |
| E.R. Squibb & Sons, L.L.C. | 3 | $67 |
| Teva Pharmaceuticals USA, Inc. | 2 | $52 |
| Janssen Pharmaceuticals, Inc | 1 | $27 |
| ABBVIE INC. | 1 | $14 |
| Luye Pharma (USA) Ltd. | 1 | $14 |
Products named: INGREZZA, ABILIFY ASIMTUFII, ARISTADA, COBENFY, UZEDY, SPRAVATO, ABILIFY MAINTENA, VRAYLAR.
Industry payments across LA — which companies pay providers there.
